Welcome to our dedicated page for Rockwell Med news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Med stock.
Rockwell Medical Inc (RMTI) delivers innovative therapies for chronic kidney disease and hemodialysis patients, including the only FDA-approved iron replacement therapy administered via dialysate. This page provides investors and healthcare professionals with centralized access to official press releases, clinical trial updates, and business developments directly impacting renal care innovation.
Track RMTI's progress in advancing dialysis solutions like triferic® and critical concentrates that maintain metabolic balance during treatment. Stay informed about regulatory milestones, partnership announcements, and research breakthroughs that shape the company's role in improving patient outcomes.
Key updates across three focus areas: iron deficiency management advancements, dialysis product innovations, and strategic initiatives enhancing renal care delivery. Bookmark this resource for verified information on RMTI's contributions to reducing treatment complications in ESRD patients.
Rockwell Medical, a healthcare company focused on hemodialysis products, reported a 26.0% increase in fourth-quarter revenue, reaching $19.3 million, and an annual revenue of $72.8 million in 2022, up 17.6% year-over-year. The company significantly reduced its debt from $21.6 million to $10.0 million and lowered operational cash usage to $594,000 from $9.0 million in Q4 2021. Despite a net loss of $2.4 million for Q4 and $18.7 million for the full year, Rockwell aims for profitability with 2023 guidance projecting sales between $78.0 million and $82.0 million.
Rockwell Medical (Nasdaq: RMTI) will showcase its hemodialysis concentrates portfolio at DialysisTechConneXion40 (DTX40) from March 28-31, 2023, in Las Vegas, Nevada. The Company is exhibiting at Booth #502, featuring products like CitraPure® Citric Acid Concentrate and Dri-Sate® Dry Acid Concentrate. Rockwell Medical is recognized as the second-largest supplier of acid and bicarbonate concentrates for dialysis in the U.S. The Company aims to enhance its offerings and provide quality service to dialysis providers while striving to become the leading global supplier of hemodialysis concentrates.
Rockwell Medical (Nasdaq: RMTI) has achieved Great Place to Work Certification™ in 2023 during its first year of participation. This recognition is based solely on employee feedback regarding workplace experiences, emphasizing high-trust environments. The certification reflects Rockwell’s commitment to providing quality products and exceptional customer service for dialysis clinics and patients. With a mission to enhance hemodialysis care, Rockwell is the second-largest supplier of dialysis concentrates in the U.S. and aims to become a global leader in this sector.
Rockwell Medical, Inc. (Nasdaq: RMTI) announced it will release its financial and operational results for Q4 and the full year ending December 31, 2022, on March 30, 2023, at 6:00 AM ET. A live conference call will follow at 8:00 AM ET, where management will discuss the results, including operational performance and future outlook. Rockwell Medical is recognized as the second largest supplier of hemodialysis products in the U.S., focusing on improving patient care through innovative healthcare solutions.
Rockwell Medical, Inc. (Nasdaq: RMTI) has signed a three-year product purchase agreement with Concerto Renal Services, the largest provider of dialysis in skilled nursing facilities in the U.S. The agreement positions Rockwell as the primary supplier of hemodialysis concentrates, contributing millions in annual revenue. The U.S. hemodialysis concentrates market is valued at $380 million, projected to grow to $500 million by 2026, driven by an increase in end-stage kidney disease patients. Rockwell aims for profitability in 2024, emphasizing its commitment to becoming a global leader in the sector.
Rockwell Medical (RMTI) has secured a multi-million dollar, three-year product purchase agreement with the largest non-profit dialysis provider in the U.S. This agreement positions Rockwell as the preferred supplier of liquid and dry acid and bicarbonate concentrates to hemodialysis facilities nationwide. CEO Mark Strobeck expressed enthusiasm, emphasizing this deal as a foundation for revenue growth and profitability by 2024. The hemodialysis concentrates market is valued at $380 million, with projections reaching $500 million by 2026 due to rising end-stage kidney disease cases. Rockwell is the second largest supplier in this vital market.
Rockwell Medical (NASDAQ: RMTI) has expanded its business into Minnesota, supplying hemodialysis concentrates to clinics there since December 5, 2022. The company anticipates onboarding all clinics by January 1, 2023, expecting over $1 million in revenue in the first year. As the second-largest U.S. supplier of these products, Rockwell is well-positioned in a market expected to grow from $380 million to $500 million by 2026 due to increasing end-stage kidney disease cases. The company aims for annual revenue of $100 million in the coming years.
Rockwell Medical, Inc. (RMTI) is restructuring to capitalize on the hemodialysis market, aiming for profitability in 2024. The company reduced long-term debt from $15 million to $10 million and achieved a record quarterly revenue of $18.7 million for Q3 2022, marking a 16.9% year-over-year increase. Cash used in operations fell by 81% to $1.1 million. Rockwell is reacquiring distribution rights for its hemodialysis concentrates and expects annual revenue could reach $100 million soon. Despite challenges, the company maintains high demand for its products.
Rockwell Medical (NASDAQ: RMTI) is reacquiring distribution rights for its hemodialysis concentrates from Baxter, effective November 9, 2022. This strategic move allows Rockwell to sell products directly to over 700 dialysis customers, enhancing profitability and operational independence. The U.S. market for these products is projected to grow from $380 million to $500 million by 2026. Rockwell aims for $100 million in annual revenue in the coming years and expects profitability by 2024, reducing reliance on external funding.
Rockwell Medical, Inc. (NASDAQ:RMTI) will release its financial results for Q3 2022 on November 14, 2022, at 6:00am ET. A live conference call will follow at 8:00am ET, led by CEO Mark Strobeck and CFO Russell Skibsted, discussing the financial and operational results. Investors can join the call by dialing (888) 660-6347 or via international number (929) 201-6594. The results will be available on the company’s website, RockwellMed.com, with a replay accessible until December 14, 2022.
FAQ
What is the current stock price of Rockwell Med (RMTI)?
What is the market cap of Rockwell Med (RMTI)?
